Proinflammatory cytokines have several functions including activation of the hypothalamo-pituitary-adrenal (HPA) axis and regulation of the immune system. The present study focuses on the regulation of interleukin 12 (IL-12) and its receptor gene expression in the HPA axis under artificially induced immune stress, brought on by administration of lipopolysaccharide (LPS) to Sprague-Dawley (SD) rats. RT-PCR analyses showed that expression of the IL-12 p40 gene was significantly increased and peaked at 2 h in the pituitary gland, but not in the hypothalamus. LPS-induced IL-12 p40 gene induction in the pituitary gland was suppressed after β-adrenoceptor agonist pretreatment in vivo. Both IL-12 p40 gene induction and IL-12 production were also observed when freshly isolated pituitary glands from non-treated SD rats were incubated with LPS in vitro. Furthermore, CD14, which is known as a LPS receptor, was found to be expressed in the pituitary gland. Gel mobility shift assays using nuclear extracts prepared from the pituitary glands of rats administered LPS showed induction of NF-ĸB and AP-1 DNA-binding activity. These results suggest that LPS stimulates the pituitary gland directly in vivo to increase IL-12 p40 gene expression and IL-12 protein production.

1.
Chrousos GP: Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann NY Acad Sci 1998;851:311–335.
2.
Satta MA, Jacobs RA, Kaltsas GA, Grossman AB: Endotoxin induces interleukin-1beta and nitric oxide synthase mRNA in rat hypothalamus and pituitary. Neuroendocrinology 1998;67:109–116.
3.
Spangelo BL, Judd AM, MacLeod RM, Goodman DW, Isakson PC: Endotoxin-induced release of interleukin-6 from rat medial basal hypothalami. Endocrinology 1990;127:1779–1785.
4.
Arras M, Hoche A, Bohle R, Eckert P, Riedel W, Schaper J: Tumor necrosis factor-alpha in macrophages of heart, liver, kidney, and in the pituitary gland. Cell Tissue Res 1996;285:39–49.
5.
Besedovsky H, del Rey A, Sorkin E, Dinarello CA: Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986;233:652–654.
6.
van der Meer MJ, Sweep CG, Rijnkels CE, Pesman GJ, Tilders FJ, Kloppenborg PW, Hermus AR: Acute stimulation of the hypothalamic-pituitary-adrenal axis by IL-1 beta, TNF alpha and IL-6:A dose response study. J Endocrinol Invest 1996;19:175–182.
7.
van der Meer MJ, Sweep CG, Pesman GJ, Borm GF, Hermus AR: Synergism between IL-1 beta and TNF-alpha on the activity of the pituitary-adrenal axis and on food intake of rats. Am J Physiol 1995;268:E551–E557.
8.
Sharp BM, Matta SG, Peterson PK, Newton R, Chao C, McAllen K: Tumor necrosis factor-alpha is a potent ACTH secretagogue: Comparison to interleukin-1 beta. Endocrinology 1989;124:3131–3133.
9.
Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690–1694.
10.
Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP: Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: Potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 1994;79:934–939.
11.
Suzuki S, Oh C, Nakano K: Pituitary-dependent and -independent secretion of CS caused by bacterial endotoxin in rats. Am J Physiol 1986;250:E470–E474.
12.
Elenkov IJ, Kovacs K, Kiss J, Bertok L, Vizi ES: Lipopolysaccharide is able to bypass corticotrophin-releasing factor in affecting plasma ACTH and corticosterone levels: Evidence from rats with lesions of the paraventricular nucleus. J Endocrinol 1992;133:231–236.
13.
Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827–845.
14.
Stalder AK, Pagenstecher A, Yu NC, Kincaid C, Chiang CS, Hobbs MV, Bloom FE, Campbell IL: Lipopolysaccharide-induced IL-12 expression in the central nervous system and cultured astrocytes and microglia. J Immunol 1997;159:1344–1351.
15.
Szabo C, Hasko G, Zingarelli B, Nemeth ZH, Salzman AL, Kvetan V, Pastores SM, Vizi ES: Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology 1997;90:95–100.
16.
Hasko G, Nemeth ZH, Szabo C, Zsilla G, Salzman AL, Vizi ES: Isoproterenol inhibits IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages. Brain Res Bull 1998;45:183–187.
17.
Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG, Choi I: Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 2000;164:6287–6295.
18.
Xie H, Chiles TC, Rothstein TL: Induction of CREB activity via the surface Ig receptor of B cells. J Immunol 1993;151:880–889.
19.
Pierce JW, Lenardo M, Baltimore D: Oligonucleotide that binds nuclear factor NF-kappa B acts as a lymphoid-specific and inducible enhancer element. Proc Natl Acad Sci USA 1988;85:1482–1486.
20.
Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, Jonat C, Herrlich P, Karin M: Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 1987;49:729–739.
21.
Kim H, Ko JP, Kang UG, Park JB, Kim HL, Lee YH, Kim YS: Electroconvulsive shock reduces inositol 1,4,5-triphosphate 3-kinase mRNA expression in rat dentate gyrus. J Neurochem 1994;63:1991–1994.
22.
Spangelo BL, Jarvis WD, Judd AM, MacLeod RM: Induction of interleukin-6 release by interleukin-1 in rat anterior pituitary cells in vitro: Evidence for an eicosanoid-dependent mechanism. Endocrinology 1991;129:2886–2894.
23.
Zhang JS, Feng WG, Li CL, Wang XY, Chang ZL: NF-kappa B regulates the LPS-induced expression of interleukin 12 p40 in murine peritoneal macrophages: Roles of PKC, PKA, ERK, p38 MAPK, and proteasome. Cell Immunol 2000;204:38–45.
24.
Verhagen CE, de Boer T, Smits HH, Verreck FA, Wierenga EA, Kurimoto M, Lammas DA, Kumararatne DS, Sanal O, Kroon FP, van Dissel JT, Sinigaglia F, Ottenhoff TH: Residual type 1 immunity in patients genetically deficient for interleukin 12 receptor beta1 (IL-12Rbeta1): evidence for an IL-12Rbeta1-independent pathway of IL-12 responsiveness in human T cells. J Exp Med 2000;192:517–528.
25.
Stahel PF, Kossmann T, Joller H, Trentz O, Morganti-Kossmann MC: Increased interleukin-12 levels in human cerebrospinal fluid following severe head trauma. Neurosci Lett 1998;249:123–126.
26.
Lissoni P, Rovelli F, Rivolta MR, Frigerio C, Mandala M, Barni S, Ardizzoia A, Malugani F, Tancini G: Acute endocrine effects of interleukin-12 in cancer patients. J Biol Regul Homeost Agents 1997;11:154–156.
27.
Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409–417.
28.
Quan N, Whiteside M, Herkenham M: Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience 1998;83:281–293.
29.
Spangelo BL, MacLeod RM, Isakson PC: Production of interleukin-6 by anterior pituitary cells in vitro. Endocrinology 1990;126:582–586.
30.
Conti B, Jahng JW, Tinti C, Son JH, Joh TH: Induction of interferon-gamma inducing factor in the adrenal cortex. J Biol Chem 1997;272:2035–2037.
31.
Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W: Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987;238:522–524.
32.
Uehara A, Gottschall PE, Dahl RR, Arimura A: Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor. Endocrinology 1987;121:1580–1582.
33.
Berkenbosch F, van Oers J, del Rey A, Tilders F, Besedovsky H: Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987;238:524–526.
34.
Whiteside MB, Quan N, Herkenharn M: Induction of pituitary cytokine transcripts by peripheral lipopolysaccharide. J Neuroendocrinol 1999;11:115–120.
35.
Lenczowski MJ, Van Dam AM, Poole S, Larrick JW, Tilders FJ: Role of circulating endotoxin and interleukin-6 in the ACTH and corticosterone response to intraperitoneal LPS. Am J Physiol 1997;273:R1870–R1877.
36.
Givalois L, Arancibia S, Tapia-Arancibia L: Concomitant changes in CRH mRNA levels in rat hippocampus and hypothalamus following immobilization stress. Brain Res Mol Brain Res 2000;75:166–171.
37.
Yi SJ, Baram TZ: Corticotropin-releasing hormone mediates the response to cold stress in the neonatal rat without compensatory enhancement of the peptide’s gene expression. Endocrinology 1994;135:2364–2368.
38.
Severn A, Rapson NT, Hunter CA, Liew FY: Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol 1992;148:3441–3445.
39.
Suberville S, Bellocq A, Fouqueray B, Philippe C, Lantz O, Perez J, Baud L: Regulation of interleukin-10 production by beta-adrenergic agonists. Eur J Immunol 1996;26:2601–2605.
40.
Elenkov IJ, Hasko G, Kovacs KJ, Vizi ES: Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by selective alpha- and beta-adrenergic drugs in mice. J Neuroimmunol 1995;61:123–131.
41.
Panina-Bordignon P, Mazzeo D, Lucia PD, D’Ambrosio D, Lang R, Fabbri L, Self C, Sinigaglia F: Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997;100:1513–1519.
42.
Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP: Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: Clinical implications. Proc Assoc Am Physicians 1996;108:374–381.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.